Biodel inks agreement with HEC Pharm for ultra-rapid-acting insulin aspart formulation
Biodel announced a research supply and technology development agreement with the HEC Pharm subsidiary Yichang Chang Jiang Pharmaceutical, for ultra-rapid-acting insulin aspart. HEC will supply insulin aspart which Biodel will use to formulate aspart based ultra-rapid-acting insulin formulations. April 22, 2014